• Oncopeptides

    Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen, a novel lipophilic peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC). Melflufen is in development as a new treatment for the hematological cancer multiple myeloma.

  • Audiocast regarding clinical program update

    Oncopeptides held an audiocast April 24, where Jakob Lindberg, CEO, provided new guidance on the patient recruitment in the OCEAN study and a clinical program update. The audiocast was recorded.

About melflufen

Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytotoxic payload into myeloma cells through peptidase activity. It belongs to the novel class Peptidase Enhanced Cytotoxics (PEnC), which is a family of lipophilic peptides that exhibit increased activity via peptidase cleavage and have the potential to treat many cancers.

Jefferies 2018 London Healthcare conference – Presentation & webcast

Oncopeptides CEO Jakob Lindberg held a presentation at Jefferies 2018 Healthcare conference in London November 14. The presentation was also recorded as a webcast.

Mechanism of action

Melflufen (Ygalo®) is a peptide conjugated alkylator belonging to a novel class of peptidase-enhanced cytotoxics (PEnC), targets multiple myeloma (MM) cells with a unique mechanism of action.

Back to top